Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Post-Mkt 03-20 16:47:37 EDT

0.3511

+0.0149

+4.43%

盘后0.3442

-0.0069-1.97%

16:35 EDT

High0.3700	Low0.3350	Vol1.78M
Open0.3380	D1 Closing0.3362	Amplitude10.41%
Mkt Cap29.16M	Tradable Cap23.78M	Total Shares83.07M
T/O617.84K	T/O Rate2.62%	Tradable Shares67.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.3511,"timestamp":1774036800000,"preClose":0.3362,"halted":0,"volume":1776679,"hourTrading":{"tag":"盘后","latestPrice":0.3442,"preClose":0.3511,"latestTime":"16:35 EDT","volume":1218,"amount":417.41191296,"timestamp":1774038901489,"change":-0.0069,"changeRate":-0.019653,"amplitude":0.038735},"delay":0,"changeRate":0.04431885782272464,"floatShares":67733200,"shares":83067200,"eps":-2.89,"marketStatus":"Post-Mkt","change":0.0149,"latestTime":"03-20 16:47:37 EDT","open":0.338,"high":0.37,"low":0.335,"amount":617841.3659253,"amplitude":0.104105,"askPrice":0.3799,"askSize":100,"bidPrice":0.333,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.89,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774051200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.3362,"preHourTrading":{"tag":"盘前","latestPrice":0.3362,"preClose":0.3362,"latestTime":"08:16 EDT","volume":17632,"amount":6031.24035776,"timestamp":1774008982744,"change":0,"changeRate":0,"amplitude":0.019631},"postHourTrading":{"tag":"盘后","latestPrice":0.3442,"preClose":0.3511,"latestTime":"16:35 EDT","volume":1218,"amount":417.41191296,"timestamp":1774038901489,"change":-0.0069,"changeRate":-0.019653,"amplitude":0.038735},"volumeRatio":0.794894,"impliedVol":2.2354,"impliedVolPercentile":0.761},"requestUrl":"/m/hq/s/OTLK","defaultTab":"news","newsList":[{"id":"2619686764","title":"Outlook Therapeutics Inc - Extends Maturity Date of Existing Convertible Note to December 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619686764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619686764?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA1BNLFM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2619468937","title":"Outlook Therapeutics Inc - Enters $18.4 Mln New Note, Expects $17 Mln Net Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468937?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA1BNLFM:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2619468907","title":"Outlook Therapeutics Inc - Lender Confirms Existing Note Is Not in Default","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468907","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468907?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA1BNLFM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2619118468","title":"Outlook Therapeutics Inc - Proceeds From New Note to Pay Down Existing Note, $10.8 Mln Principal and Interest Remaining on Existing Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2619118468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619118468?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA1BNLFM:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2619450024","title":"Press Release: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450024?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., March 16, 2026  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Capital, LLC  and the issuance of a new non-convertible, unsecured note with Atlas Sciences, LLC .Under the amendment to the Existing Note, the maturity date of the Existing Note has been extended to December 31, 2026, with no other changes to the terms. The lender has confirmed that the Existing Note is not in default.In addition, Outlook Therapeutics entered into the $18.4 million New Note. The Company expects to receive $17 million in net proceeds, after original issue discount. Proceeds from the New Note will be used to pay down a portion of the Existing Note, reducing the balance and leaving approximately $10.8 million of principal and interest remaining on the Existing Note.The New Note bears interest at a rate equal to th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","LU1880398554.USD","LU0109392836.USD","AMDD","TM","LU2458330169.SGD","BK4573","IE00BMPRXN33.USD","BK4554","LU1064131342.USD","BK4566","BK4007","LU1242518931.SGD","03160","DAMD","LU1951200564.SGD","LU0823421333.USD","BK4141","BK4604","AMDU","LU2931357623.SGD","LU0719512351.SGD","LU1923623000.USD","AMDL","AMDW","BK4534","BK4612","LU0082616367.USD","LU2355687059.USD","AMUU","BK4588","LU1988902786.USD","BK4512","LU1951198990.SGD","LU0889565833.HKD","BK4543","OTLK","LU2458330243.SGD","LU0056508442.USD","LU1880398471.USD","BK4539","LU0390134368.USD","LU1316542783.SGD","BK4529","LU2098885051.SGD","AMDY","AMYY","AMDG","LU1989764664.SGD"],"gpt_icon":1},{"id":"2618976218","title":"Outlook Therapeutics director Julia A. Haller to step down effective March 10, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618976218","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618976218?lang=en_us&edition=fundamental","pubTime":"2026-03-12 05:17","pubTimestamp":1773263840,"startTime":"0","endTime":"0","summary":"Julia Haller will step down from the board of Outlook Therapeutics effective March 10, 2026. Haller cited time constraints after taking on new responsibilities as CEO at Wills Eye Hospital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL1FhDg2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2617995571","title":"Outlook Therapeutics provides update following FDA meeting on ONS-5010","url":"https://stock-news.laohu8.com/highlight/detail?id=2617995571","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617995571?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:55","pubTimestamp":1772747720,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) provided an update following its recent Type A meeting with the FDA to discuss the December 30, 2025 complete response ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-provides-update-following-fda-meeting-on-ons-5010-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-provides-update-following-fda-meeting-on-ons-5010-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OTLK","BK4007","LENZ","BK4539","BK4139"],"gpt_icon":0},{"id":"2617761925","title":"Outlook Therapeutics Updates on FDA Type A Meeting for ONS-5010/LYTENAVA BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2617761925","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617761925?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:15","pubTimestamp":1772745336,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics said it held a Type A meeting with the U.S. FDA to discuss the December 30, 2025 Complete Response Letter for its Biologics License Application for ONS-5010/LYTENAVA , focused on the FDA’s outstanding issue regarding substantial evidence of effectiveness and potential paths forward. The company said NORSE TWO, a randomized, double-masked, active-controlled Phase 3 trial, met its primary and key secondary endpoints and showed clinically meaningful and statistically significant improvements in visual acuity, and that NORSE EIGHT and other BLA information provided confirmatory evidence of efficacy and safety, including functional and pharmacodynamic evidence consistent with an anti-VEGF mechanism of action. Outlook Therapeutics added that no safety concerns were identified by the FDA and that it is evaluating regulatory options while continuing discussions with the agency.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL1PpgtG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","OTLK","BK4112","SG9999014039.USD","SG9999014021.USD","SG9999014005.SGD","BK4588","LU2210150020.SGD","SG9999014013.SGD","LU2095319765.USD","BK4139","LU0314104364.USD","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2617576903","title":"Outlook Therapeutics Inc - Evaluating Regulatory Options for Ons-5010/Lytenava U.S. Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2617576903","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617576903?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:15","pubTimestamp":1772745300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUAC5FVBH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2617576137","title":"Outlook Therapeutics: to Continue Engaging in Discussions With FDA to Clarify Agency's Views on Confirmatory Evidence & Appropriate Path Forward","url":"https://stock-news.laohu8.com/highlight/detail?id=2617576137","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617576137?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:15","pubTimestamp":1772745300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUAC5FVBH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2617357695","title":"Outlook Therapeutics Provides Update Following Type a Meeting With FDA Regarding Ons-5010/Lytenava™ (Bevacizumab-Vikg)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617357695","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617357695?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:15","pubTimestamp":1772745300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUAC5FVBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2612283168","title":"Outlook enters distribution agreement for sale of Lytenava in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2612283168","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612283168?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:16","pubTimestamp":1771510565,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced they have entered into an exclusive commercial distribution agreement for the sale and distribution of Lytena...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-enters-distribution-agreement-for-sale-of-lytenava-in-switzerland-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-enters-distribution-agreement-for-sale-of-lytenava-in-switzerland-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2612288254","title":"Outlook Therapeutics Signs Exclusive LYTENAVA Distribution Agreement With Mediconsult AG in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2612288254","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612288254?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:00","pubTimestamp":1771509642,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc. signed an exclusive commercial distribution agreement with Mediconsult AG for LYTENAVA  in Switzerland. Mediconsult will have exclusive rights to market, import, distribute and commercialize the product and will handle Swiss regulatory activities, including seeking and maintaining marketing authorization, while Outlook Therapeutics will remain responsible for manufacturing, product supply and related intellectual property. The companies said LYTENAVA is expected to be available in Switzerland in 2027, subject to marketing authorization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 19, 2026","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL7QqD7g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","BK4585","LU0314104364.USD","OTLK","SG9999014005.SGD","BK4139","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","BK4112"],"gpt_icon":0},{"id":"2612882272","title":"Outlook Therapeutics: Partnership Advances European Commercial Expansion Strategy, With Lytenava Expected to Launch in Switzerland in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2612882272","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612882272?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:00","pubTimestamp":1771509608,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA6FBQXM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2612428824","title":"Outlook Therapeutics Inc - Mediconsult to Market and Distribute Lytenava in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2612428824","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612428824?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:00","pubTimestamp":1771509608,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA6FBQXM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2612028826","title":"Outlook Therapeutics Expands European Footprint With Exclusive Commercial Distribution Agreement With Mediconsult Ag for Lytenava™ (Bevacizumab Gamma) in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2612028826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612028826?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:00","pubTimestamp":1771509608,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA6FBQXM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2612422838","title":"Nasdaq Warns Outlook Therapeutics of Delisting Risk After Sub-$1 Share Price Streak","url":"https://stock-news.laohu8.com/highlight/detail?id=2612422838","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612422838?lang=en_us&edition=fundamental","pubTime":"2026-02-19 06:02","pubTimestamp":1771452136,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics said it received a Nasdaq notice that its shares have traded below the $1.00 minimum bid price requirement for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5550. The company has until Aug. 17, 2026 to regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days, or it could face delisting if it cannot cure the deficiency or qualify for an additional compliance period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commiss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL54rRtZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2612176452","title":"BRIEF-Outlook Therapeutics Q1 EPS USD -0.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2612176452","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612176452?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:05","pubTimestamp":1771333546,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Q1 EPS USD -0.38\n\n\nFeb 17 (Reuters) - Outlook Therapeutics Q1 adjusted EPS USD -0.22.\n\nQ1 net income USD -23.1 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nPLXE4852C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2612436452","title":"Outlook Therapeutics posts Q1 net income of USD -23.1 million, swinging from profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2612436452","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612436452?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:05","pubTimestamp":1771333532,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc. reported a net loss attributable to common stockholders of USD 23.1 million, or USD 0.38 per basic and diluted share, for the fiscal first quarter ended December 31, 2025, compared to net income of USD 17.4 million for the same period last year. The company posted an adjusted net loss attributable to common stockholders of USD 13.5 million, or USD 0.22 per basic and diluted share, for the quarter. Adjusted net loss excludes USD 6.7 million related to loss from change in fair value. The company highlighted ongoing regulatory processes for ONS-5010 and cited macroeconomic risks, including overseas conflicts and inflation, as factors that could impact future performance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal adv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDLc2b1fq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","SG9999014039.USD","SG9999014021.USD","IE00BKPKM429.USD","BK4588","SG9999014013.SGD","LU0314104364.USD","BK4112","LU2210150020.SGD","OTLK","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","NDAQ"],"gpt_icon":0},{"id":"2612452175","title":"Outlook Therapeutics Q1 Net Income USD -23.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452175","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452175?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:05","pubTimestamp":1771333501,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nPLXE4852C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.2014},{"period":"1month","weight":-0.2039},{"period":"3month","weight":-0.8327},{"period":"6month","weight":-0.6509},{"period":"1year","weight":-0.7713},{"period":"ytd","weight":-0.7872}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.1402},{"month":3,"riseRate":0.3,"avgChangeRate":-0.064666},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.10242},{"month":5,"riseRate":0.666667,"avgChangeRate":0.154179},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.046947},{"month":7,"riseRate":0.6,"avgChangeRate":0.042124},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}